What this study is
Atrial fibrillation (AF) is an enormous public health problem in the United States, affecting 2-5 million Americans and causing rapid heart beats, stroke, heart failure or death. In this project, the applicant will develop a novel framework to better understand human AF that builds on agreement between several concepts for the disease. The applicant will develop strategies to identify AF patients who will best respond to each of several therapies, to guide personalized therapy.
Study details
- Sponsor
- Stanford University
- Conditions
- Atrial Fibrillation · Arrhythmias, Cardiac
- Enrolling
- 200 people
- Starts
- 2020-08-18
- Est. completion
- 2027-12-30
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 22 Years – 80 YearsSex ALLHealthy volunteers Not acceptedYou may qualify if
- Referred for ablation or Maze surgery at Stanford Medicine for persistent AF (i.e. which requires cardioversion to terminate and/or lasts >7 days)
- Per our clinical practice and guidelines (Calkins et al., Heart Rhythm 2018), patients will have failed or be intolerant of >or= 1 anti-arrhythmic drug. Patients after Maze surgery typically have failed prior endocardial ablation.
You can't join if
- Active coronary ischemia or decompensated heart failure
- Atrial or ventricular clot on trans-esophageal echocardiography
- Pregnancy (to minimize fluoroscopic exposure)
- Inability or unwillingness to provide informed consent
- Rheumatic valve disease (results in a unique AF phenotype)
- Thrombotic disease or venous filters
- Prior chest surgery is a relative contraindication for Maze surgery
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openStanford University
Stanford, California, United States
- Sanjiv Narayan, MD · Contact(650) 724-1850sanjiv1@stanford.edu
- Kathleen Mills, BA · Contactkmills2@stanford.edu
Recruiting
Study team
Sponsor
Stanford University
Study ID 57424
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.